{"id":"https://openalex.org/W4361239872","doi":"https://doi.org/10.1158/0008-5472.c.6505035","title":"Data from In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors","display_name":"Data from In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361239872","doi":"https://doi.org/10.1158/0008-5472.c.6505035"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.c.6505035","doi":"https://doi.org/10.1158/0008-5472.c.6505035","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6505035","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.c.6505035","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033787308","display_name":"Kevin J. Basile","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin J. Basile","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029464243","display_name":"Ethan V. Abel","orcid":"https://orcid.org/0000-0003-2922-617X","observed_orcids":["https://orcid.org/0000-0003-2922-617X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ethan V. Abel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088302670","display_name":"Neda Dadpey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neda Dadpey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050694888","display_name":"Edward J. Hartsough","orcid":"https://orcid.org/0000-0002-5109-3978","observed_orcids":["https://orcid.org/0000-0002-5109-3978"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edward J. Hartsough","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062228025","display_name":"Paolo M. Fortina","orcid":"https://orcid.org/0000-0002-5898-2081","observed_orcids":["https://orcid.org/0000-0002-5898-2081"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Fortina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5062746446","display_name":"Andrew E. Aplin","orcid":"https://orcid.org/0000-0002-2734-3244","observed_orcids":["https://orcid.org/0000-0002-2734-3244"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew E. Aplin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/raf-inhibitor-resistance","display_name":"RAF inhibitor resistance","score":0.9950000047683716},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9200000166893005},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":1.0},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.7870000004768372},{"id":"https://openalex.org/keywords/hras-mutation","display_name":"HRAS mutation","score":0.9850000143051147},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8830000162124634},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.6320000290870667},{"id":"https://openalex.org/keywords/tumor-heterogeneity","display_name":"tumor heterogeneity","score":0.7879999876022339},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.8629999756813049}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.8353747129440308},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.6262043118476868},{"id":"https://openalex.org/C1167327","wikidata":"https://www.wikidata.org/wiki/Q14884140","display_name":"HRAS","level":5,"score":0.6122066378593445},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6018710136413574},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5080420970916748},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.4962959885597229},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4757915735244751},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.4669668972492218},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4384381175041199},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4380396902561188},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.404777854681015},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.39824461936950684},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.39070966839790344},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36767107248306274},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34329700469970703},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.15933823585510254},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.15933528542518616},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.10209038853645325},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.08569073677062988},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.08564251661300659},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.c.6505035","doi":"https://doi.org/10.1158/0008-5472.c.6505035","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6505035","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.c.6505035","doi":"https://doi.org/10.1158/0008-5472.c.6505035","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.c.6505035","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2011261819","https://openalex.org/W2039390246","https://openalex.org/W1600353599","https://openalex.org/W4392686853","https://openalex.org/W1989594172","https://openalex.org/W2081295565","https://openalex.org/W2062258918","https://openalex.org/W1584909194","https://openalex.org/W1995437676","https://openalex.org/W4252868328"],"abstract_inverted_index":{"Abstract":[0],"Activation":[1],"of":[2,35,45,59,66,74,109],"the":[3,12,32,43,72,132],"ERK1/2":[4,48,75,116],"mitogen-activated":[5],"protein":[6],"kinases":[7],"(MAPK)":[8],"confers":[9],"resistance":[10,26,80,130,135],"to":[11,23,30,81],"RAF":[13,36,60,82,128],"inhibitors":[14,37],"vemurafenib":[15],"and":[16,56,89,105,113,118,131],"dabrafenib":[17],"in":[18,38,63,71,93,126,134],"mutant":[19],"BRAF-driven":[20],"melanomas.":[21],"Methods":[22],"understand":[24],"how":[25],"develops":[27],"are":[28],"important":[29],"optimize":[31],"clinical":[33],"use":[34],"patients.":[39],"Here,":[40],"we":[41],"report":[42],"development":[44],"a":[46,53,140],"novel":[47,88],"reporter":[49],"system":[50,68],"that":[51],"provides":[52],"noninvasive,":[54],"quantitative,":[55],"temporal":[57],"analysis":[58],"inhibitor":[61,129],"efficacy":[62],"vivo.":[64],"Use":[65],"this":[67],"revealed":[69],"heterogeneity":[70,133],"level":[73],"reactivation":[76,117],"associated":[77],"with":[78],"acquired":[79],"inhibition.":[83],"We":[84],"identified":[85],"several":[86],"distinct":[87],"known":[90],"molecular":[91],"changes":[92],"resistant":[94],"tumors":[95],"emerging":[96],"from":[97,139],"treatment-na\u00efve":[98],"cell":[99,142],"populations":[100],"including":[101],"BRAF":[102],"V600E":[103],"variants":[104],"HRAS":[106],"mutation,":[107],"both":[108],"which":[110,137],"were":[111],"required":[112],"sufficient":[114],"for":[115],"drug":[119],"resistance.":[120],"Our":[121],"work":[122],"offers":[123],"an":[124],"advance":[125],"understanding":[127],"mechanisms,":[136],"emerge":[138],"malignant":[141],"population.":[143],"Cancer":[144],"Res;":[145],"73(23);":[146],"7101\u201310.":[147],"\u00a92013":[148],"AACR.":[149]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-03-31T00:00:00"}